CD8A and breast cancer: We confirmed the feasibility of ECM1 as a universal TAA, identified the predominant HLA-A2.1-restricted epitopes derived from ECM1 (LA and YL), and verified their immunogenicity to induce DCs to elicit CD8+ T cells and potent cytotoxicity against breast cancer in vitro and in vivo.